FDMT Stock Summary and Trading Ideas (4D Molecular Therapeutics | NASDAQ:FDMT)

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.

As of March 19, 2026, FDMT stock price climbed to $8.98 with 658,489 million shares trading.

FDMT has a beta of 1.27, meaning it tends to be more sensitive to market movements. FDMT has a correlation of 0.06 to the broad based SPY ETF.

FDMT has a market cap of $458.05 million. This is considered a Small Cap stock.

Last quarter 4D Molecular Therapeutics reported $85 million in Revenue and $.43 earnings per share. This beat revenue expectation by $53 million and exceeded earnings estimates by $.96.

In the last 3 years, FDMT traded as high as $36.25 and as low as $2.24.

The top ETF exchange traded funds that FDMT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.

FDMT has outperformed the market in the last year with a price return of +135.1% while the SPY ETF gained +18.9%. FDMT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +3.3% and +0.6%, respectively, while the SPY returned -1.9% and -3.7%, respectively.

FDMT support price is $8.17 and resistance is $8.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.